{"id":"W4210463828","doi":"10.1016/s2468-1253(21)00382-4","title":"Pembrolizumab for previously treated advanced anal squamous cell carcinoma: results from the non-randomised, multicohort, multicentre, phase 2 KEYNOTE-158 study","year":2022,"lang":"en","type":"article","venue":"˜The œLancet. Gastroenterology & hepatology","topic":"Colorectal and Anal Carcinomas","field":"Medicine","cited_by":73,"is_retracted":false,"has_abstract":false,"ca_institutions":"McGill University","funders":"National Cancer Institute; Principia Biopharma; National Institutes of Health; BioMarin Pharmaceutical; Silverback Therapeutics; Puma Biotechnology; F-star Therapeutics; Genentech; AstraZeneca; Alexion Pharmaceuticals; Celldex Therapeutics; Amgen; Pfizer","keywords":"Medicine; Pembrolizumab; Internal medicine; Clinical endpoint; Anal cancer; Cohort; Adverse effect; Surgery; Cancer; Phases of clinical research; Clinical trial; Oncology; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0008022514,0.0005932599,0.001720165,0.0001477595,0.0007758828,0.0000258168,0.0008548769,0.0001450533,0.0001322638],"category_scores_gemma":[0.0001719001,0.0003958901,0.0005250251,0.00026164,0.0003835648,0.00005842812,0.0004779031,0.001087442,0.00001977986],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002624569,"about_ca_system_score_gemma":0.0001559264,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001518718,"about_ca_topic_score_gemma":0.005007102,"domain_scores_codex":[0.9946063,0.001229328,0.001115441,0.001181478,0.0003890843,0.001478423],"domain_scores_gemma":[0.9963617,0.001360265,0.0005716042,0.001256362,0.000188061,0.0002619734],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.3193454,0.003259983,0.6650914,0.00003518807,0.0002976534,0.0007887344,0.002686475,0.0001600408,0.002324173,0.000001944901,0.005133343,0.0008756288],"study_design_scores_gemma":[0.556154,0.03103117,0.36557,0.00001397938,0.00276095,0.0009012903,0.003959734,0.03326537,0.000355269,0.00004334467,0.005490209,0.0004546971],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9885859,0.0005104325,0.0001519019,0.00313329,0.0006936305,0.005729027,0.0008575794,0.0001182996,0.0002199338],"genre_scores_gemma":[0.9926918,0.00002155038,0.0001295585,0.003803755,0.0006650825,0.001538165,0.0006993428,0.0000740653,0.000376749],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2995214,"threshold_uncertainty_score":0.9998493,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02118178989392829,"score_gpt":0.2783420517374179,"score_spread":0.2571602618434896,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}